[{"id":"88f3eaef-14f2-44c3-90f7-c4ebafee84e8","acronym":"","url":"https://clinicaltrials.gov/study/NCT07474064","created_at":"2026-03-28T01:40:03.816Z","updated_at":"2026-03-28T01:40:03.816Z","phase":"Phase 2","brief_title":"Probiotics Combined With Targeted Therapy Plus Immunotherapy in Bladder-Preserving Setting for Patients With MIBC","source_id_and_acronym":"NCT07474064","lead_sponsor":"chenxu","biomarkers":" HER-2","pipe":" | ","alterations":" HER-2 expression","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Loqtorzi (toripalimab-tpzi) • Aidixi (disitamab vedotin) • Cdactin-O (CBM588)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 146","initiation":"Initiation: 03/26/2026","start_date":" 03/26/2026","primary_txt":" Primary completion: 03/31/2031","primary_completion_date":" 03/31/2031","study_txt":" Completion: 03/31/2035","study_completion_date":" 03/31/2035","last_update_posted":"2026-03-17"},{"id":"778d6e97-aaea-4385-b9ac-14c267296d2e","acronym":"","url":"https://clinicaltrials.gov/study/NCT07474324","created_at":"2026-03-28T01:42:37.705Z","updated_at":"2026-03-28T01:42:37.705Z","phase":"Phase 2","brief_title":"Disitamab Vedotin Combined With SOX Regimen Versus SOX Alone as Adjuvant Therapy for HER2-Moderate/High Expressing Stage Ⅲ Gastric Cancer: A Prospective, Multicenter, Randomized, Phase Ⅱ Clinical Trial","source_id_and_acronym":"NCT07474324","lead_sponsor":"The First Affiliated Hospital with Nanjing Medical University","biomarkers":" HER-2","pipe":" | ","alterations":" HER-2 overexpression • HER-2 expression","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 overexpression • HER-2 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e oxaliplatin • Aidixi (disitamab vedotin)"],"overall_status":"Recruiting","enrollment":" Enrollment 124","initiation":"Initiation: 03/15/2026","start_date":" 03/15/2026","primary_txt":" Primary completion: 12/31/2028","primary_completion_date":" 12/31/2028","study_txt":" Completion: 12/31/2030","study_completion_date":" 12/31/2030","last_update_posted":"2026-03-16"},{"id":"ec6be1b2-4bb2-4f7d-914f-ec7b055df2df","acronym":"DECIDING","url":"https://clinicaltrials.gov/study/NCT07142200","created_at":"2025-08-30T13:52:10.410Z","updated_at":"2025-08-30T13:52:10.410Z","phase":"Phase 2","brief_title":"A Clinical Study Evaluating the Efficacy and Safety of Disitamab Vedotin Combined With PD-1 Inhibitor and Radiotherapy as Bladder-preserving Therapy in Patients With Localized HER2-high Expressing Muscle-invasive Bladder Urothelial Carcinoma Following Maximal Transurethral Resection","source_id_and_acronym":"NCT07142200 - DECIDING","lead_sponsor":"RenJi Hospital","biomarkers":" PD-L1","pipe":"","alterations":" ","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Aidixi (disitamab vedotin)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 45","initiation":"Initiation: 09/01/2025","start_date":" 09/01/2025","primary_txt":" Primary completion: 06/30/2026","primary_completion_date":" 06/30/2026","study_txt":" Completion: 12/31/2027","study_completion_date":" 12/31/2027","last_update_posted":"2025-08-26"},{"id":"251e3807-7c32-48ca-b5d8-dd58192012fb","acronym":"DIVON","url":"https://clinicaltrials.gov/study/NCT06957561","created_at":"2025-09-07T01:29:15.570Z","updated_at":"2025-09-07T01:29:15.570Z","phase":"Phase 1/2","brief_title":"Disitamab Vedotin Combined With Ivonescimab in Cisplatin-Ineligible Muscle-Invasive Bladder Cancer","source_id_and_acronym":"NCT06957561 - DIVON","lead_sponsor":"Sun Yat-sen University","biomarkers":" PD-L1","pipe":"","alterations":" ","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Aidixi (disitamab vedotin) • Yidafan (ivonescimab)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 30","initiation":"Initiation: 04/30/2025","start_date":" 04/30/2025","primary_txt":" Primary completion: 05/01/2026","primary_completion_date":" 05/01/2026","study_txt":" Completion: 05/01/2029","study_completion_date":" 05/01/2029","last_update_posted":"2025-05-04"},{"id":"624a9976-a05c-4b20-8113-57cccfb1cb75","acronym":"KEYNOTE-D78","url":"https://clinicaltrials.gov/study/NCT04879329","created_at":"2021-05-10T14:53:12.740Z","updated_at":"2025-02-25T13:53:47.511Z","phase":"Phase 2","brief_title":"A Study of Disitamab Vedotin Alone or With Pembrolizumab in Urothelial Cancer That Expresses HER2","source_id_and_acronym":"NCT04879329 - KEYNOTE-D78","lead_sponsor":"Seagen Inc.","biomarkers":" HER-2","pipe":" | ","alterations":" HER-2 expression","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • Aidixi (disitamab vedotin)"],"overall_status":"Recruiting","enrollment":" Enrollment 372","initiation":"Initiation: 05/03/2022","start_date":" 05/03/2022","primary_txt":" Primary completion: 11/30/2026","primary_completion_date":" 11/30/2026","study_txt":" Completion: 05/30/2028","study_completion_date":" 05/30/2028","last_update_posted":"2025-02-20"},{"id":"8d3fc0b2-6af5-4276-b9b3-c9f1505975ad","acronym":"KEYNOTE-D74","url":"https://clinicaltrials.gov/study/NCT05911295","created_at":"2023-06-22T20:09:18.721Z","updated_at":"2025-02-25T13:55:18.081Z","phase":"Phase 3","brief_title":"Disitamab Vedotin With Pembrolizumab vs Chemotherapy in Previously Untreated Urothelial Cancer Expressing HER2","source_id_and_acronym":"NCT05911295 - KEYNOTE-D74","lead_sponsor":"Seagen Inc.","biomarkers":" HER-2","pipe":" | ","alterations":" HER-2 expression","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • cisplatin • carboplatin • gemcitabine • Aidixi (disitamab vedotin)"],"overall_status":"Recruiting","enrollment":" Enrollment 400","initiation":"Initiation: 09/22/2023","start_date":" 09/22/2023","primary_txt":" Primary completion: 06/30/2026","primary_completion_date":" 06/30/2026","study_txt":" Completion: 04/30/2029","study_completion_date":" 04/30/2029","last_update_posted":"2025-02-20"},{"id":"683158be-dd0a-42cf-9640-03e574df768d","acronym":"SGNDV-005","url":"https://clinicaltrials.gov/study/NCT06003231","created_at":"2023-08-21T14:09:07.249Z","updated_at":"2025-02-25T16:40:09.136Z","phase":"Phase 2","brief_title":"A Study of Disitamab Vedotin in Previously Treated Solid Tumors That Express HER2","source_id_and_acronym":"NCT06003231 - SGNDV-005","lead_sponsor":"Seagen Inc.","biomarkers":" HER-2","pipe":" | ","alterations":" HER-2 expression","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Aidixi (disitamab vedotin)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 122","initiation":"Initiation: 11/14/2023","start_date":" 11/14/2023","primary_txt":" Primary completion: 05/31/2026","primary_completion_date":" 05/31/2026","study_txt":" Completion: 05/31/2028","study_completion_date":" 05/31/2028","last_update_posted":"2025-02-07"},{"id":"b85874df-7e06-4405-a134-b832b090826f","acronym":"RCTS","url":"https://clinicaltrials.gov/study/NCT05586061","created_at":"2022-10-19T13:56:28.812Z","updated_at":"2025-02-25T16:33:09.486Z","phase":"Phase 2","brief_title":"First-line Treatment with RC48 Plus Tislelizumab and S-1(RCTS) in Advanced Gastric Cancer","source_id_and_acronym":"NCT05586061 - RCTS","lead_sponsor":"Qilu Hospital of Shandong University","biomarkers":" HER-2","pipe":"","alterations":" ","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Tevimbra (tislelizumab-jsgr) • Aidixi (disitamab vedotin) • Teysuno (gimeracil/oteracil/tegafur)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 55","initiation":"Initiation: 02/10/2023","start_date":" 02/10/2023","primary_txt":" Primary completion: 12/29/2024","primary_completion_date":" 12/29/2024","study_txt":" Completion: 12/31/2025","study_completion_date":" 12/31/2025","last_update_posted":"2025-02-07"},{"id":"b1bfb829-6051-48a2-8e1d-95a6b089f5de","acronym":"","url":"https://clinicaltrials.gov/study/NCT06038396","created_at":"2023-09-14T14:13:03.466Z","updated_at":"2025-02-25T17:39:19.635Z","phase":"Phase 1/2","brief_title":"A Study of RC118 Plus Toripalimab / RC148 in Patients with Locally Advanced Unresectable or Metastatic Solid Tumors","source_id_and_acronym":"NCT06038396","lead_sponsor":"RemeGen Co., Ltd.","biomarkers":" CLDN18","pipe":" | ","alterations":" CLDN1 positive","tags":["CLDN18"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CLDN1 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Loqtorzi (toripalimab-tpzi) • Aidixi (disitamab vedotin) • ciletatug vedotin (RC118)"],"overall_status":"Recruiting","enrollment":" Enrollment 48","initiation":"Initiation: 08/03/2023","start_date":" 08/03/2023","primary_txt":" Primary completion: 02/28/2026","primary_completion_date":" 02/28/2026","study_txt":" Completion: 08/31/2026","study_completion_date":" 08/31/2026","last_update_posted":"2025-01-29"},{"id":"83f56344-90cd-467e-b21a-af268ac41927","acronym":"neovision","url":"https://clinicaltrials.gov/study/NCT06734182","created_at":"2025-02-25T19:17:44.245Z","updated_at":"2025-02-25T19:17:44.245Z","phase":"Phase 2","brief_title":"Neoadjuvant Envafolimab Plus Disitamab Vedotin and Carboplatin in Resectable HER2-Mutant Non-Small-Cell Lung Cancer","source_id_and_acronym":"NCT06734182 - neovision","lead_sponsor":"Guangdong Provincial People's Hospital","biomarkers":" HER-2","pipe":" | ","alterations":" PD-L1 expression • HER-2 expression","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression • HER-2 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e carboplatin • Aidixi (disitamab vedotin) • Enweida (envafolimab)"],"overall_status":"Recruiting","enrollment":" Enrollment 25","initiation":"Initiation: 06/22/2024","start_date":" 06/22/2024","primary_txt":" Primary completion: 06/22/2027","primary_completion_date":" 06/22/2027","study_txt":" Completion: 06/22/2028","study_completion_date":" 06/22/2028","last_update_posted":"2024-12-16"},{"id":"7ae24087-c472-4aeb-9770-168fd262ba6d","acronym":"DAB","url":"https://clinicaltrials.gov/study/NCT06540729","created_at":"2025-02-25T19:17:09.926Z","updated_at":"2025-02-25T19:17:09.926Z","phase":"Phase 2","brief_title":"Disitamab Vedotin (RC48) in Combination With AK104 (PD-1/CTLA-4 Bispecific) and Bevacizumab for the Treatment of Recurrent and Persistent Clear Cell Ovarian Cancer: a Single-arm, Phase II, Multicenter Study (DAB OCC Study)","source_id_and_acronym":"NCT06540729 - DAB","lead_sponsor":"Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University","biomarkers":" MSI","pipe":"","alterations":" ","tags":["MSI"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Avastin (bevacizumab) • Aidixi (disitamab vedotin) • Kaitanni (cadonilimab)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 39","initiation":"Initiation: 07/31/2024","start_date":" 07/31/2024","primary_txt":" Primary completion: 08/01/2028","primary_completion_date":" 08/01/2028","study_txt":" Completion: 08/01/2030","study_completion_date":" 08/01/2030","last_update_posted":"2024-08-06"},{"id":"a52c3104-0f9a-4050-865e-f342d9805c67","acronym":"HCCSC-C03","url":"https://clinicaltrials.gov/study/NCT05661357","created_at":"2022-12-22T15:59:20.868Z","updated_at":"2024-07-02T16:35:09.314Z","phase":"Phase 4","brief_title":"Disitamab Vedotin Combined With Fruquintinib for mCRC With HER2 Expression","source_id_and_acronym":"NCT05661357 - HCCSC-C03","lead_sponsor":"Zhongnan Hospital","biomarkers":" HER-2","pipe":" | ","alterations":" HER-2 amplification • HER-2 mutation • HER-2 expression","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 amplification • HER-2 mutation • HER-2 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Aidixi (disitamab vedotin) • Fruzaqla (fruquintinib)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 51","initiation":"Initiation: 01/01/2023","start_date":" 01/01/2023","primary_txt":" Primary completion: 01/31/2025","primary_completion_date":" 01/31/2025","study_txt":" Completion: 12/31/2025","study_completion_date":" 12/31/2025","last_update_posted":"2024-04-17"},{"id":"dd93d217-a333-439e-aa8e-029a17abbff7","acronym":"","url":"https://clinicaltrials.gov/study/NCT06105008","created_at":"2023-10-27T17:14:07.187Z","updated_at":"2024-07-02T16:35:18.462Z","phase":"Phase 2","brief_title":"Study of Disitamab Vedotin With Toripalimab Verus Disitamab Vedotin in Hormone Receptor Positive, HER2-low Locally Advanced or Metastatic Breast Cancer","source_id_and_acronym":"NCT06105008","lead_sponsor":"RemeGen Co., Ltd.","biomarkers":" HER-2 • ER","pipe":" | ","alterations":" HER-2 expression • HER-2 underexpression • PGR expression","tags":["HER-2 • ER"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 expression • HER-2 underexpression • PGR expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Loqtorzi (toripalimab-tpzi) • Aidixi (disitamab vedotin)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 80","initiation":"Initiation: 12/20/2024","start_date":" 12/20/2024","primary_txt":" Primary completion: 12/20/2025","primary_completion_date":" 12/20/2025","study_txt":" Completion: 04/10/2026","study_completion_date":" 04/10/2026","last_update_posted":"2024-02-21"},{"id":"0e8ea207-e06b-48ee-b343-407d2f69f755","acronym":"","url":"https://clinicaltrials.gov/study/NCT05297552","created_at":"2022-03-28T13:52:54.238Z","updated_at":"2024-07-02T16:35:18.720Z","phase":"Phase 2","brief_title":"A Study of RC48-ADC Combined With JS001 For Perioperative Treatment of Muscle-Invasive Bladder Cancer","source_id_and_acronym":"NCT05297552","lead_sponsor":"RemeGen Co., Ltd.","biomarkers":" HER-2","pipe":" | ","alterations":" HER-2 expression","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Loqtorzi (toripalimab-tpzi) • Aidixi (disitamab vedotin)"],"overall_status":"Recruiting","enrollment":" Enrollment 40","initiation":"Initiation: 05/26/2022","start_date":" 05/26/2022","primary_txt":" Primary completion: 06/01/2024","primary_completion_date":" 06/01/2024","study_txt":" Completion: 02/28/2025","study_completion_date":" 02/28/2025","last_update_posted":"2024-02-20"},{"id":"1585c471-2d5f-4b62-9460-634d77535830","acronym":"","url":"https://clinicaltrials.gov/study/NCT05135715","created_at":"2021-11-26T14:53:38.599Z","updated_at":"2024-07-02T16:35:18.511Z","phase":"Phase 2","brief_title":"A Study of RC48-ADC in Advanced Melanoma Subjects With HER2 Variant (Mutation, Amplification, Overexpression)","source_id_and_acronym":"NCT05135715","lead_sponsor":"RemeGen Co., Ltd.","biomarkers":" HER-2","pipe":"","alterations":" ","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Aidixi (disitamab vedotin)"],"overall_status":"Recruiting","enrollment":" Enrollment 50","initiation":"Initiation: 04/19/2022","start_date":" 04/19/2022","primary_txt":" Primary completion: 12/30/2024","primary_completion_date":" 12/30/2024","study_txt":" Completion: 12/30/2025","study_completion_date":" 12/30/2025","last_update_posted":"2024-02-20"},{"id":"f06e2b3b-190c-464f-ad53-5bf7da6d993f","acronym":"","url":"https://clinicaltrials.gov/study/NCT03500380","created_at":"2021-01-18T17:14:21.163Z","updated_at":"2024-07-02T16:35:18.748Z","phase":"Phase 2/3","brief_title":"A Study of RC48-ADC Administered Intravenously to Patients With HER2-Positive Metastatic Breast Cancer With or Without Liver Metastases","source_id_and_acronym":"NCT03500380","lead_sponsor":"RemeGen Co., Ltd.","biomarkers":" HER-2","pipe":" | ","alterations":" HER-2 positive • HER-2 expression","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 positive • HER-2 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e lapatinib • capecitabine • Aidixi (disitamab vedotin)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 301","initiation":"Initiation: 04/24/2018","start_date":" 04/24/2018","primary_txt":" Primary completion: 07/31/2024","primary_completion_date":" 07/31/2024","study_txt":" Completion: 12/31/2024","study_completion_date":" 12/31/2024","last_update_posted":"2024-02-20"},{"id":"c3b5e701-e66f-42af-8315-cc08cb5dd2ed","acronym":"","url":"https://clinicaltrials.gov/study/NCT05403242","created_at":"2022-06-03T12:55:12.504Z","updated_at":"2024-07-02T16:35:24.297Z","phase":"Phase 1/2","brief_title":"RC48-ADC Combined With S-1 for First-line Treatment of Advanced Gastroesophageal Adenocarcinoma With Moderate Expression of HER2","source_id_and_acronym":"NCT05403242","lead_sponsor":"Chinese PLA General Hospital","biomarkers":" HER-2","pipe":"","alterations":" ","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Aidixi (disitamab vedotin) • Teysuno (gimeracil/oteracil/tegafur)"],"overall_status":"Recruiting","enrollment":" Enrollment 42","initiation":"Initiation: 09/20/2022","start_date":" 09/20/2022","primary_txt":" Primary completion: 09/01/2025","primary_completion_date":" 09/01/2025","study_txt":" Completion: 09/01/2026","study_completion_date":" 09/01/2026","last_update_posted":"2024-01-08"},{"id":"d6a118c2-8cf3-4103-9203-82d15917f3c9","acronym":"","url":"https://clinicaltrials.gov/study/NCT06185400","created_at":"2023-12-29T18:18:16.940Z","updated_at":"2024-07-02T16:35:24.913Z","phase":"Phase 2","brief_title":"RC48 Combined With EGFR or HER2 TKI for Locally Advanced or Metastatic NSCLC Patients With HER2 Alterations","source_id_and_acronym":"NCT06185400","lead_sponsor":"Cancer Institute and Hospital, Chinese Academy of Medical Sciences","biomarkers":" HER-2","pipe":"","alterations":" ","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Tagrisso (osimertinib) • Irene (pyrotinib) • Ameile (aumolertinib) • Aidixi (disitamab vedotin) • Ivesa (firmonertinib)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 108","initiation":"Initiation: 02/01/2024","start_date":" 02/01/2024","primary_txt":" Primary completion: 07/01/2025","primary_completion_date":" 07/01/2025","study_txt":" Completion: 12/01/2026","study_completion_date":" 12/01/2026","last_update_posted":"2023-12-29"},{"id":"09fc7827-ede0-47b8-bfad-87886f2f2991","acronym":"","url":"https://clinicaltrials.gov/study/NCT04714190","created_at":"2021-01-19T20:53:05.479Z","updated_at":"2024-07-02T16:35:25.513Z","phase":"Phase 3","brief_title":"A Study of RC48-ADC in Local Advanced or Metastatic Gastric Cancer With the HER2-Overexpression","source_id_and_acronym":"NCT04714190","lead_sponsor":"RemeGen Co., Ltd.","biomarkers":" HER-2","pipe":" | ","alterations":" HER-2 overexpression","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 overexpression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e paclitaxel • AiTan (rivoceranib) • irinotecan • Aidixi (disitamab vedotin)"],"overall_status":"Recruiting","enrollment":" Enrollment 351","initiation":"Initiation: 03/24/2021","start_date":" 03/24/2021","primary_txt":" Primary completion: 12/01/2024","primary_completion_date":" 12/01/2024","study_txt":" Completion: 06/30/2025","study_completion_date":" 06/30/2025","last_update_posted":"2023-12-21"},{"id":"d0cfca12-83a1-4ae6-a039-eec24053140c","acronym":"","url":"https://clinicaltrials.gov/study/NCT04329429","created_at":"2021-01-18T20:58:05.247Z","updated_at":"2024-07-02T16:35:25.640Z","phase":"Phase 2","brief_title":"A Study of RC48-ADC in Subjects With HER2 Overexpressed Metastatic Biliary Tract Cancer","source_id_and_acronym":"NCT04329429","lead_sponsor":"RemeGen Co., Ltd.","biomarkers":" HER-2","pipe":" | ","alterations":" HER-2 overexpression","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 overexpression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Aidixi (disitamab vedotin)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 57","initiation":"Initiation: 08/24/2020","start_date":" 08/24/2020","primary_txt":" Primary completion: 11/03/2023","primary_completion_date":" 11/03/2023","study_txt":" Completion: 06/30/2024","study_completion_date":" 06/30/2024","last_update_posted":"2023-12-20"},{"id":"19a18864-7900-47b9-9910-14ea9b2a17e8","acronym":"","url":"https://clinicaltrials.gov/study/NCT05514158","created_at":"2022-08-24T21:07:48.157Z","updated_at":"2024-07-02T16:35:26.025Z","phase":"Phase 1","brief_title":"To Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of Disitamab Vedotin Combined With RC98 in the Treatment of Subjects With HER2-expressing Locally Advanced or Metastatic Gastric Cancer (Including AEG)","source_id_and_acronym":"NCT05514158","lead_sponsor":"RemeGen Co., Ltd.","biomarkers":" HER-2","pipe":"","alterations":" ","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Aidixi (disitamab vedotin) • RC98"],"overall_status":"Recruiting","enrollment":" Enrollment 24","initiation":"Initiation: 09/28/2022","start_date":" 09/28/2022","primary_txt":" Primary completion: 05/30/2024","primary_completion_date":" 05/30/2024","study_txt":" Completion: 09/30/2024","study_completion_date":" 09/30/2024","last_update_posted":"2023-12-18"},{"id":"3a8265dc-ee83-41bf-9af2-f4486ee102ab","acronym":"","url":"https://clinicaltrials.gov/study/NCT05302284","created_at":"2022-03-31T18:52:46.613Z","updated_at":"2024-07-02T16:35:25.953Z","phase":"Phase 3","brief_title":"A Study of RC48-ADC Combined With Toripalimab For First-line Treatment of Urothelial Carcinoma","source_id_and_acronym":"NCT05302284","lead_sponsor":"RemeGen Co., Ltd.","biomarkers":" HER-2","pipe":" | ","alterations":" HER-2 expression","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cisplatin • carboplatin • gemcitabine • Loqtorzi (toripalimab-tpzi) • Aidixi (disitamab vedotin)"],"overall_status":"Recruiting","enrollment":" Enrollment 452","initiation":"Initiation: 06/14/2022","start_date":" 06/14/2022","primary_txt":" Primary completion: 12/31/2026","primary_completion_date":" 12/31/2026","study_txt":" Completion: 04/30/2028","study_completion_date":" 04/30/2028","last_update_posted":"2023-12-18"},{"id":"3d91b73f-1374-4bd6-8a0d-ade3bfd4c4ef","acronym":"","url":"https://clinicaltrials.gov/study/NCT04965519","created_at":"2021-07-16T13:53:24.630Z","updated_at":"2024-07-02T16:35:26.022Z","phase":"Phase 2","brief_title":"A Study of RC48-ADC for the Treatment of HER2-expressing Gynecological Malignancies","source_id_and_acronym":"NCT04965519","lead_sponsor":"RemeGen Co., Ltd.","biomarkers":" HRD • BRCA • MUC16","pipe":" | ","alterations":" HER-2 expression • HRD • BRCA mutation","tags":["HRD • BRCA • MUC16"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 expression • HRD • BRCA mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Aidixi (disitamab vedotin)"],"overall_status":"Recruiting","enrollment":" Enrollment 120","initiation":"Initiation: 12/21/2021","start_date":" 12/21/2021","primary_txt":" Primary completion: 10/01/2024","primary_completion_date":" 10/01/2024","study_txt":" Completion: 06/01/2025","study_completion_date":" 06/01/2025","last_update_posted":"2023-12-18"},{"id":"6b2bb63b-dc20-4b24-a942-bc8fc5df4024","acronym":"","url":"https://clinicaltrials.gov/study/NCT04073602","created_at":"2021-01-18T19:57:12.133Z","updated_at":"2024-07-02T16:35:26.033Z","phase":"Phase 2","brief_title":"A Study of RC48-ADC in Subjects With HER2-negative Locally Advanced or Metastatic Urothelial Cancer","source_id_and_acronym":"NCT04073602","lead_sponsor":"RemeGen Co., Ltd.","biomarkers":" HER-2","pipe":" | ","alterations":" HER-2 negative","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cisplatin • Aidixi (disitamab vedotin)"],"overall_status":"Completed","enrollment":" Enrollment 19","initiation":"Initiation: 08/19/2019","start_date":" 08/19/2019","primary_txt":" Primary completion: 09/30/2022","primary_completion_date":" 09/30/2022","study_txt":" Completion: 01/31/2023","study_completion_date":" 01/31/2023","last_update_posted":"2023-12-18"}]